Clinical trials: ACP3
Prostate Cancer
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
Phase II trial to study the effectiveness of APC8015 combined with bevacizumab in treating patients who have undergone radiation therapy and/or surgery and who have progressive prostate cancer.
- Trial name
- NCT00027599
- Testing
- bevacizumab, prostatic acid phosphatase-sargramostim fusion protein, sipuleucel-T
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer (Diagnosis), ACP3
68Ga-XMFH01 PET/Fluorescence Imaging in Prostate Cancer
This study aims to evaluate the feasibility, safety, and diagnostic performance of 68Ga-XMFH01, a novel ACP3-targeted dual-modality PET and fluorescence imaging probe, for preoperative PET/CT imaging and intraoperative…
- Conditions
- Prostate Cancer (Diagnosis), ACP3, PET / CT
- Trial name
- NCT07885423
- Testing
- 68Ga-XMFH01 PET/CT
- Where
- China
- Volunteers
- 25 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Ischemia Reperfusion Injury, Endothelial Dysfunction
Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury
Rationale: Apart from their cholesterol lowering effects, statins have cholesterol-independent pleiotropic actions, such as upregulation of 5'-ectonucleotidase and up-regulation of NO-synthase that may increase tolerance against…
- Trial name
- NCT00987974
- Testing
- rosuvastatin, atorvastatin 3 days, rosuvastatin 7 days
- Where
- Netherlands
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Prostatic Neoplasms, Prostate Cancer
Diagnostic Performance of ACP3-Targeted PET Imaging in Patients With Primary and Recurrent Prostate Cancer: An Open-Label, Single-Arm, Single-Center Study
This study aims to evaluate the diagnostic performance of [68Ga]Ga-OncoACP3 PET imaging, which targets prostate acid phosphatase (ACP3), in men with clinically suspected or confirmed high-risk prostate cancer, or suspected…
- Trial name
- NCT07830212
- Testing
- [68Ga]Ga-OncoACP3
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Yong He
Castration-resistant Prostate Cancer, Metastatic Cancer
pTVG-HP DNA Vaccine With or Without pTVG-AR DNA Vaccine and Pembrolizumab in Patients With Castration-Resistant, Metastatic Prostate Cancer
This trial will evaluate the use of one versus two DNA vaccines, delivered concurrently with PD-1 blockade using pembrolizumab followed by treatment with pembrolizumab alone, and delivered over a prolonged period of time (for a…
- Conditions
- Castration-resistant Prostate Cancer, Metastatic Cancer, Prostate Cancer
- Trial name
- NCT04090528
- Testing
- pTVG-HP, pTVG-AR, Pembrolizumab
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer
The aim of this study is to assess the safety and dosimetry of imaging with [68Ga]Ga-OncoACP3 in patients with prostate cancer.
- Trial name
- SWAP (NCT07600554)
- Testing
- [68Ga]Ga-OncoACP3
- Where
- 2 sites in Italy
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Prostate Cancer
pTVG-HP and Nivolumab in Patients With Non-Metastatic PSA-Recurrent Prostate Cancer
The purpose of this study is to evaluate the safety of an investigational DNA vaccine, pTVG-HP, a plasmid DNA encoding human prostatic acid phosphatase (PAP), in combination with nivolumab, and the efficacy of this combination in…
- Trial name
- NCT03600350
- Testing
- pTVG-HP, Nivolumab, GM-CSF
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Two-Arm Study of a DNA Vaccine Encoding Prostatic Acid Phosphatase (PAP) in Patients With Non-Metastatic Castrate-Resistant Prostate Cancer
The investigators are trying to find new methods to treat prostate cancer. The approach is to try to enhance patients' own immune response against the cancer.
- Trial name
- NCT00849121
- Testing
- pTVG-HP with rhGM-CSF
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer Patients, Non-castrate Prostate Cancer
Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC
The goal of this clinical trial is to learn whether an experimental vaccine called pTVG-HP ("vaccine" or "DNA vaccine"), combined with a drug called nivolumab can increase the cancer-fighting ability of a person's immune cells.
- Conditions
- Prostate Cancer Patients, Non-castrate Prostate Cancer, Recurrent Prostate Cancer, Oligometastatic Prostate Cancer (OMPC)
- Trial name
- NCT07090148
- Testing
- pTVG-HP DNA vaccine, Anti-PD-1 monoclonal antibody
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Wisconsin, Madison
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer
Proposed immunotherapy with an extended course of Sipuleucel-T treatment may induce a more robust immune response and improve the anti-cancer efficacy of Sipuleucel-T in patients with metastatic Castration-Resistant Prostate…
- Trial name
- OU-SCC-EXCITE (NCT05806814)
- Testing
- Sipuleucel-T
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Oklahoma
Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate
RYZ711 Diagnostic Platform Study
This is a Phase 1/2 multicenter, multi-cohort imaging study to evaluate the safety, tolerability, and diagnostic performance of RYZ711 positron emission tomography/computed tomography (PET/CT) in men with histologically confirmed…
- Conditions
- Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate, Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
- Trial name
- NCT07862582
- Testing
- RYZ711, PSMA PET/CT
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- RayzeBio, Inc.
Prostate Cancer (Diagnosis)
Theranostic Applications of Radionuclides in Prostate Cancer
The objective of the study is to construct a noninvasive approach ACP3 targeted PET/CT to detect tumor lesions in patients with prostate cancer and to compare with PSMA/FDG PET/CT.
- Trial name
- NCT07559201
- Testing
- standard-of-care imaging (PSMA/FDG PET/CT), ACP3 PET/CT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guilin Medical University, China
Infertility Unexplained
Effect of Oral Zinc Sulfate Supplementation on Enzymes of Urate Pathway
Although many reports have investigated the relationship between subfertility and uric acid levels in semen, to the best of author knowledge, there is no study have been published to yet focus on the effects of asthenospermia…
- Trial name
- NCT03361618
- Testing
- Zinc Sulfate
- Where
- Iraq
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Babylon University
Prostate Cancer, PET/CT
68Ga-XACP3 PET/CT in Prostate Cancer
The objective of the study is to construct a noninvasive approach 68Ga-XACP3 PET/CT to detect tumor lesions in patients with prostate cancer and to compare with 68Ga-PSMA PET/CT.
- Conditions
- Prostate Cancer, PET/CT, ACP3
- Trial name
- NCT07242014
- Testing
- Diagnostic Test: standard-of-care imaging (68Ga-PSMA PET/CT), 68Ga-XACP3 PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
5'-Nucleotidase Syndrome
Phase II Study of Ribose, Uridine, and Thymidine for a Complex Syndrome Involving Excessive 5'-Nucleotidase Activity
OBJECTIVES: I. Evaluate the efficacy of oral ribose in patients with a complex 5'-nucleotidase syndrome who have not received uridine (UR) and thymidine (TDR). II. Evaluate the efficacy of UR/oral ribose and UR/TDR. III.
- Trial name
- NCT00004658
- Testing
- ribose, thymidine, uridine
- Sponsor
- National Center for Research Resources (NCRR)
Prostate Cancer
Prostatic Acid Phosphatase (PAP) Vaccine in Patients With Prostate Cancer
The investigators are trying to find new methods to treat prostate cancer. The approach they investigators are taking is to try to enhance patients own immune response against the cancer.
- Trial name
- NCT00582140
- Testing
- pTVG-HP with rhGM-CSF
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer.
- Trial name
- NCT01341652
- Testing
- pTVG-HP, rhGM-CSF
- Where
- 3 sites in United States
- Volunteers
- 99 people
- Sponsor
- University of Wisconsin, Madison